DEVELOPING
Importance
62
Trust
76
Urgency
65
CLINICAL TRIAL✓ 2 outlets
STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
Pfizer showed new details from a midstage trial of its obesity drug berobenatide, which the company bought from Metsera. The drug appears to work when given once a month instead of more often.
Analysis
Pfizer's once-a-month obesity drug shows promise in mid-stage testing. A monthly shot could be easier for patients than weekly options.
- Pfizer showed new details from a midstage trial of berobenatide
- Pfizer bought berobenatide from Metsera
- Drug appears to work when given once a month
STAT News — Pharma14d
Read